TheraRadar
← Back
Data updated: Jun 28, 2026

MICRO LABS LTD

Generics

MICRO LABS LTD is a generic drug manufacturer focused on Cardiovascular, Neurology, Respiratory. Key products include LAMIVUDINE, NEVIRAPINE AND ZIDOVUDINE.

1988
Since
94
Drugs
-
Trials
1
New Drugs (2yr)
Modality:
1 Small Molecules

MICRO LABS LTD's Key Drugs

MICRO LABS LTD's core commercial portfolio centers on CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE, DICLOFENAC SODIUM AND MISOPROSTOL, OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE, spanning Cardiovascular and Neurology — its most strategically important drugs approved in the last 15 years.

MICRO LABS LTD's Therapeutic Areas

MICRO LABS LTD's approved drugs and pipeline span 5 therapeutic areas, led by Cardiovascular and Neurology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Cardiovascular 44%
15 drugs
Neurology 21%
7 drugs
Respiratory 12%
4 drugs
Immunology 12%
4 drugs
Infectious Disease 12%
4 drugs

MICRO LABS LTD Pipeline Snapshot

Active clinical trials for MICRO LABS LTD across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE leads revenue
  • 5 key drugs tracked

Trial Catalysts

  • Cardiovascular pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling